Johnson & Johnson $JNJ Shares Acquired by Tokio Marine Asset Management Co. Ltd.

Tokio Marine Asset Management Co. Ltd. lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.6% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 80,491 shares of the company’s stock after acquiring an additional 2,796 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Johnson & Johnson were worth $14,925,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Gill Capital Partners LLC lifted its position in shares of Johnson & Johnson by 2.9% during the 3rd quarter. Gill Capital Partners LLC now owns 2,434 shares of the company’s stock worth $451,000 after buying an additional 69 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. raised its stake in Johnson & Johnson by 0.4% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 6,179,488 shares of the company’s stock worth $1,145,801,000 after acquiring an additional 21,819 shares in the last quarter. Cornell Pochily Investment Advisors Inc. boosted its stake in Johnson & Johnson by 7.0% in the third quarter. Cornell Pochily Investment Advisors Inc. now owns 20,621 shares of the company’s stock valued at $3,823,000 after acquiring an additional 1,343 shares in the last quarter. Mowery & Schoenfeld Wealth Management LLC grew its holdings in shares of Johnson & Johnson by 311.9% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 865 shares of the company’s stock worth $160,000 after purchasing an additional 655 shares during the last quarter. Finally, First Horizon Corp acquired a new stake in shares of Johnson & Johnson during the third quarter worth about $26,658,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 2.3%

JNJ stock opened at $218.53 on Thursday. The stock has a market capitalization of $526.51 billion, a PE ratio of 21.09, a price-to-earnings-growth ratio of 2.19 and a beta of 0.34. The company has a fifty day moving average of $204.52 and a 200-day moving average of $186.04. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. Johnson & Johnson has a one year low of $141.50 and a one year high of $218.86.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 14th. The company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.76 by $0.04. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $23.99 billion during the quarter, compared to analysts’ expectations of $23.73 billion. During the same period in the prior year, the company posted $2.42 earnings per share. The firm’s revenue for the quarter was up 6.8% on a year-over-year basis. As a group, analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is 50.19%.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. BMO Capital Markets reissued an “outperform” rating on shares of Johnson & Johnson in a research report on Thursday, December 11th. Scotiabank assumed coverage on shares of Johnson & Johnson in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $230.00 target price on the stock. Daiwa America upgraded shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. Weiss Ratings reissued a “buy (b)” rating on shares of Johnson & Johnson in a research report on Friday, October 31st. Finally, Sanford C. Bernstein upped their target price on shares of Johnson & Johnson from $193.00 to $208.00 and gave the company a “market perform” rating in a report on Friday, January 9th. Four analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $213.33.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Phase 3 MajesTEC-9 topline: TECVAYLI (teclistamab) monotherapy showed a 71% reduction in risk of progression or death and a 40% reduction in risk of death versus standard of care in early-relapse, largely anti?CD38/lenalidomide?refractory myeloma — a potentially significant new earlier-line oncology opportunity that can drive revenue and R&D upside. TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide
• Positive Sentiment: Delaware court orders recalculation of damages in Auris/robotics case — the state’s top court overturned part of a ~$1B award and ordered a recalculation that could materially reduce J&J’s payout exposure, lowering legal risk on the balance sheet. Court Orders Recalculation Of Damages In Johnson & Johnson Auris Case
• Positive Sentiment: MedTech momentum: Zacks highlights growth driven by cardiovascular strength and new product rollouts, supporting the MedTech segment’s contribution even as China weakness lingers — a constructive signal for recurring revenue. What’s Powering J&J’s MedTech Growth Ahead of Q4 Release?
• Positive Sentiment: Psychiatry pipeline/data: New CAPLYTA and SPRAVATO analyses being presented at ACNP reinforce J&J’s CNS franchise and could support future label or adoption upside. Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting
• Neutral Sentiment: Company expected to report quarterly results this week — keep an eye on guidance, MedTech trends and margins; earnings timing may create short-term volatility but is routine. Johnson & Johnson (JNJ) Projected to Post Quarterly Earnings on Wednesday
• Neutral Sentiment: Investor attention spikes: Zacks notes heavy search/interest in JNJ — increased attention can amplify moves around data and earnings. Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
• Neutral Sentiment: Dividend visibility: JNJ features in dividend-focused lists (Dogs of the Dow coverage); this underpins income investor interest but is unlikely to move shares materially on its own. The Dogs of the Dow: 10 Downtrodden Dividends Paying Out Up to 6.8%
• Negative Sentiment: Zacks preview flags J&J may lack the setup for an earnings beat next week — if results or guidance disappoint, that could reverse some of today’s gains. Johnson & Johnson (JNJ) Reports Next Week: Wall Street Expects Earnings Growth

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.